Chemed Toekomstige groei

Future criteriumcontroles 1/6

De verwachting is dat Chemed de winst en omzet met respectievelijk 8.8% en 6.2% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 8.8% per jaar.

Belangrijke informatie

8.8%

Groei van de winst

8.8%

Groei van de winst per aandeel

Healthcare winstgroei	20.9%
Inkomstengroei	6.2%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	18 Nov 2024

Recente toekomstige groei-updates

The Chemed Corporation (NYSE:CHE) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

Nov 01

Chemed Corporation (NYSE:CHE) Full-Year Results: Here's What Analysts Are Forecasting For This Year

Mar 01

Recent updates

The Chemed Corporation (NYSE:CHE) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

Nov 01

Chemed Corporation's (NYSE:CHE) Business Is Yet to Catch Up With Its Share Price

Oct 29

Here's Why Chemed Corporation's (NYSE:CHE) CEO Compensation Is The Least Of Shareholders' Concerns

May 14

Is Chemed Corporation (NYSE:CHE) Trading At A 50% Discount?

Apr 26

Chemed Corporation (NYSE:CHE) Full-Year Results: Here's What Analysts Are Forecasting For This Year

Mar 01

The Price Is Right For Chemed Corporation (NYSE:CHE)

Dec 30

Chemed: Continues To Compound Shareholder Value At Double-Digit Returns

Nov 30

Chemed (NYSE:CHE) Is Aiming To Keep Up Its Impressive Returns

Oct 26

Chemed - Showcasing Why It's So Reliable

Aug 26

Chemed: Still Bullish On Economic Characteristics, But Risks Shouldn't Be Overlooked

Aug 13

Is Chemed Corporation (NYSE:CHE) Worth US$521 Based On Its Intrinsic Value?

Aug 01

Capital Investments At Chemed (NYSE:CHE) Point To A Promising Future

Jul 14

Chemed (NYSE:CHE) Has A Rock Solid Balance Sheet

Jun 07

Chemed (NYSE:CHE) Is Aiming To Keep Up Its Impressive Returns

Apr 09

Chemed Q4 2022 Earnings Preview

Feb 22

Chemed Corporation: Long-Term Tailwinds, But Remains A Hold

Feb 14

Is Chemed (NYSE:CHE) Using Too Much Debt?

Jan 05

Here's What Chemed's (NYSE:CHE) Strong Returns On Capital Mean

Dec 17

Chemed declares $0.38 dividend

Nov 04

Chemed Q3 2022 Earnings Preview

Oct 28

Does Chemed (NYSE:CHE) Have A Healthy Balance Sheet?

Oct 01

Winst- en omzetgroeiprognoses

NYSE:CHE - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	2,724	359	N/A	N/A	2
12/31/2025	2,599	345	N/A	N/A	3
12/31/2024	2,427	305	N/A	N/A	3
9/30/2024	2,377	302	313	361	N/A
6/30/2024	2,336	301	253	300	N/A
3/31/2024	2,293	283	302	354	N/A
12/31/2023	2,264	273	273	330	N/A
9/30/2023	2,225	245	259	322	N/A
6/30/2023	2,187	226	280	345	N/A
3/31/2023	2,165	240	208	269	N/A
12/31/2022	2,135	250	253	310	N/A
9/30/2022	2,129	262	220	273	N/A
6/30/2022	2,141	277	284	334	N/A
3/31/2022	2,142	267	249	303	N/A
12/31/2021	2,139	269	250	309	N/A
9/30/2021	2,132	308	271	332	N/A
6/30/2021	2,121	303	283	344	N/A
3/31/2021	2,091	329	450	507	N/A
12/31/2020	2,080	319	430	489	N/A
9/30/2020	2,069	271	410	466	N/A
6/30/2020	2,021	263	413	470	N/A
3/31/2020	1,992	231	258	317	N/A
12/31/2019	1,939	220	248	301	N/A
9/30/2019	1,874	209	238	294	N/A
6/30/2019	1,837	201	218	275	N/A
3/31/2019	1,806	205	241	296	N/A
12/31/2018	1,783	206	234	287	N/A
9/30/2018	1,753	206	152	202	N/A
6/30/2018	1,727	190	N/A	183	N/A
3/31/2018	1,700	113	N/A	159	N/A
12/31/2017	1,667	98	N/A	162	N/A
9/30/2017	1,642	76	N/A	198	N/A
6/30/2017	1,617	67	N/A	162	N/A
3/31/2017	1,592	114	N/A	197	N/A
12/31/2016	1,577	109	N/A	135	N/A
9/30/2016	1,572	106	N/A	187	N/A
6/30/2016	1,566	108	N/A	175	N/A
3/31/2016	1,557	111	N/A	166	N/A
12/31/2015	1,543	110	N/A	172	N/A
9/30/2015	1,524	110	N/A	172	N/A
6/30/2015	1,496	106	N/A	135	N/A
3/31/2015	1,475	103	N/A	134	N/A
12/31/2014	1,456	99	N/A	110	N/A
9/30/2014	1,425	92	N/A	66	N/A
6/30/2014	1,408	85	N/A	111	N/A
3/31/2014	1,405	76	N/A	131	N/A
12/31/2013	1,413	77	N/A	151	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei CHE ( 8.8% per jaar) ligt boven de spaarquote ( 2.6% ).

Winst versus markt: De winst van CHE ( 8.8% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 15.4% per jaar).

Hoge groeiwinsten: De winst van CHE zal naar verwachting groeien, maar niet aanzienlijk.

Omzet versus markt: De omzet van CHE ( 6.2% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 8.9% per jaar).

Hoge groei-inkomsten: De omzet van CHE ( 6.2% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van CHE naar verwachting over 3 jaar hoog zal zijn

Chemed Toekomstige groei

Future criteriumcontroles 1/6

Belangrijke informatie

Recente toekomstige groei-updates

The Chemed Corporation (NYSE:CHE) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

Chemed Corporation Revises Consolidated Earnings Guidance for the Full Year 2024

Chemed Corporation Reiterates Earnings Guidance for Full Year 2024

Price target increased by 10% to US$690

Chemed Corporation (NYSE:CHE) Full-Year Results: Here's What Analysts Are Forecasting For This Year

Chemed Corporation Provides Earnings Guidance for the Full-Year 2023

Recent updates

Executive Vice President recently sold US$566k worth of stock

Third quarter dividend of US$0.50 announced

Chemed Corporation Declares Quarterly Dividend, Payable on December 6, 2024

The Chemed Corporation (NYSE:CHE) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

Third quarter 2024 earnings: EPS misses analyst expectations

Now 29% undervalued after recent price drop

Chemed Corporation Revises Consolidated Earnings Guidance for the Full Year 2024

Chemed Corporation's (NYSE:CHE) Business Is Yet to Catch Up With Its Share Price

CEO, President & Director recently sold US$1.2m worth of stock

Chemed Corporation to Report Q3, 2024 Results on Oct 29, 2024

Executive Vice President recently sold US$975k worth of stock

Executive Vice President exercised options and sold US$1.6m worth of stock

Capital Investments At Chemed (NYSE:CHE) Point To A Promising Future

Chemed Remains A Buy On Long-Term Economics

VP & Director notifies of intention to sell stock

Second quarter dividend increased to US$0.50

Chemed Corporation Declares Quarterly Dividend, Payable on August 30, 2024

Executive Vice President recently sold US$1.1m worth of stock

Executive Vice President notifies of intention to sell stock

Second quarter 2024 earnings: EPS misses analyst expectations

Chemed Corporation's (NYSE:CHE) Shares May Have Run Too Fast Too Soon

Chemed Corporation to Report Q2, 2024 Results on Jul 24, 2024

CEO, President & Director recently sold US$816k worth of stock

CEO, President & Director notifies of intention to sell stock

First quarter dividend of US$0.40 announced

Chemed Corporation Declares Quarterly Dividend, Payable on June 18, 2024

Chemed: Growth Does Not Justify The Current Stock Price

CEO, President & Director recently sold US$2.3m worth of stock

Here's Why Chemed Corporation's (NYSE:CHE) CEO Compensation Is The Least Of Shareholders' Concerns

Is Chemed Corporation (NYSE:CHE) Trading At A 50% Discount?

Chemed Corporation Reiterates Earnings Guidance for Full Year 2024

First quarter 2024 earnings: EPS misses analyst expectations

Chemed Corporation, Annual General Meeting, May 20, 2024

New major risk - Revenue and earnings growth

Executive Vice President exercised options and sold US$3.8m worth of stock

Executive Vice President recently sold US$1.3m worth of stock

Chemed Corporation to Report Q1, 2024 Results on Apr 24, 2024

Price target increased by 10% to US$690

Chemed Corporation (NYSE:CHE) Full-Year Results: Here's What Analysts Are Forecasting For This Year

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Now 22% overvalued after recent price rise

Third quarter dividend of US$0.40 announced

Chemed Corporation Declares Quarterly Dividend, Payable on March 15, 2024

Chemed Corporation to Report Q4, 2023 Results on Feb 27, 2024

The Price Is Right For Chemed Corporation (NYSE:CHE)

Chemed Corporation Appoints Michael D. Witzeman as Chief Financial Officer, Effective January 1, 2024

CEO, President & Director recently sold US$859k worth of stock

Chemed: Continues To Compound Shareholder Value At Double-Digit Returns

Executive Vice President recently sold US$580k worth of stock

Executive VP & CFO notifies of intention to sell stock

Chemed Corporation Announces the Retirement of David P. Williams as Chief Financial Officer Effective December 31, 2023

Chemed Corporation Announces the Retirement of David P. Williams as Chief Financial Officer Effective December 31, 2023

Executive VP & CFO exercised options to buy US$5.9m worth of stock.

CEO, President & Director recently sold US$1.7m worth of stock

Chemed Corporation Provides Earnings Guidance for the Full-Year 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Chemed (NYSE:CHE) Is Aiming To Keep Up Its Impressive Returns

Chemed Corporation to Report Q3, 2023 Results on Oct 25, 2023

Chemed - Showcasing Why It's So Reliable

Chemed: Still Bullish On Economic Characteristics, But Risks Shouldn't Be Overlooked

CEO, President & Director recently sold US$2.1m worth of stock

Is Chemed Corporation (NYSE:CHE) Worth US$521 Based On Its Intrinsic Value?

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Capital Investments At Chemed (NYSE:CHE) Point To A Promising Future

Chemed Corporation to Report Q2, 2023 Results on Jul 26, 2023

Chemed (NYSE:CHE) Has A Rock Solid Balance Sheet

Executive Vice President notifies of intention to sell stock

Independent Director recently sold US$160k worth of stock

Independent Director notifies of intention to sell stock